Follow the NextCure, Inc. share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €27.9m. The latest transaction was filed on 12 August 2026 (Cession). Among the most active insiders: ADAR1 Capital Management, LLC. The full history is accessible without an account.
14
Insider Decl.
n/a
Thresholds
€1m
13 ops.
Buy Volume
€159,907
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NextCure, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$22.50.
38Σ signal
Buys €1m€159,907 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,600 shares@ US$5.009.1% of flowCommon StockSEC:0001940272-26-000012:3
Canonical exit: 27 Oct 2026 (T+90)
14 of 14 declarations
About NextCure, Inc.
NextCure, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapies. It utilizes its drug discovery platform to identify new therapeutic targets.